Clinical Trials for Giant Cell Arteritis (GCA)

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

NCT ID: NCT07108387

This clinical trial is studying the best way to manage a medicine called tocilizumab (also known as ACTEMRA®) in people with giant cell arteritis (GCA), a condition that causes inflammation of bloo...

Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients

NCT ID: NCT07060274

This clinical trial is studying how quickly a certain sign called the “halo sign” disappears from the blood vessels in people with Giant Cell Arteritis (GCA) after they start steroid treatment. GCA...

Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis

NCT ID: NCT06742671

This clinical trial is studying a new, faster way to diagnose Giant Cell Arteritis (GCA), a condition that causes inflammation of the blood vessels and mostly affects people over 50. GCA can lead t...

oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound

NCT ID: NCT07001059

This clinical trial is looking at a new way to help diagnose a condition called Giant Cell Arteritis (GCA), which is an inflammation of the blood vessels that can cause serious health issues. Resea...

Dual Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

NCT ID: NCT06887062

The DERAIL-LVV trial is studying a condition called large vessel vasculitis, which can lead to serious issues like heart attacks and strokes by damaging blood vessels. Researchers believe that a bo...

Bosentan in the Treatment of Giant Cell Arteritis

NCT ID: NCT06957002

The clinical trial titled "Bosentan in the Treatment of Giant Cell Arteritis" is looking to find out if adding a medication called bosentan to the usual treatment can help patients with Giant Cell ...

AYLo - AutoimmunitY and Loss of y

NCT ID: NCT06696027

The AYLo study is researching how certain genetic changes, specifically the loss of the Y chromosome in blood cells, may affect autoimmune diseases, which are conditions where the body's immune sys...

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

NCT ID: NCT05479448

This clinical trial is studying how well patients with newly-diagnosed Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) respond to steroid treatment. Researchers want to understand if ce...

Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

NCT ID: NCT06833411

The GISCO study is a clinical trial that aims to find out if an 8-week treatment with a medication called tocilizumab is as effective as a longer 26-week treatment with cortisone (a type of steroid...

A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

NCT ID: NCT06766552

This clinical trial is studying the safety and effectiveness of a new treatment called Vunakizumab for patients with various rheumatic diseases, including ankylosing spondylitis, psoriatic arthriti...

Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases

NCT ID: NCT06763783

Pilot Study to EvaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)

NCT ID: NCT06609668

The THROPIQ clinical trial is studying whether a blood test for a protein called thrombomodulin can help doctors determine if someone with pseudo-polyarthritis rheumatica (PPR) also has giant cell ...

TocILizumab in aorTitis in GCA (TILT)

NCT ID: NCT06271018

The TILT trial is an observational study being conducted in France to evaluate the safety and effectiveness of a biosimilar version of tocilizumab in treating aortitis related to Giant Cell Arterit...